In yesterday’s Wall Street session, Cybin Inc (AMEX:CYBN) shares traded at $0.48, down -5.71% from the previous session.
As of this writing, 5 analysts cover Cybin Inc (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.50, we find $5.00. Given the previous closing price of $0.51, this indicates a potential upside of 880.39 percent. CYBN stock price is now -9.14% away from the 50-day moving average and 19.42% away from the 200-day moving average. The market capitalization of the company currently stands at $196.97M.
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $5.13 as their price target over the next twelve months.
A total of 26.67% of the company’s stock is owned by insiders.
Wednesday morning saw Cybin Inc (AMEX: CYBN) opened at $0.5200. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.74. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.89, and a quick ratio of 2.89. The fifty day moving average price for CYBN is $0.5272 and a two-hundred day moving average price translates $0.4011 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Sep, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
